Cargando…

Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury

PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Jadidi, Khosrow, Panahi, Yunes, Ebrahimi, Ali, Mafi, Mostafa, Nejat, Farhad, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329699/
https://www.ncbi.nlm.nih.gov/pubmed/25709764
http://dx.doi.org/10.4103/2008-322X.150803
_version_ 1782357477479677952
author Jadidi, Khosrow
Panahi, Yunes
Ebrahimi, Ali
Mafi, Mostafa
Nejat, Farhad
Sahebkar, Amirhossein
author_facet Jadidi, Khosrow
Panahi, Yunes
Ebrahimi, Ali
Mafi, Mostafa
Nejat, Farhad
Sahebkar, Amirhossein
author_sort Jadidi, Khosrow
collection PubMed
description PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. RESULTS: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. CONCLUSION: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury.
format Online
Article
Text
id pubmed-4329699
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43296992015-02-23 Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury Jadidi, Khosrow Panahi, Yunes Ebrahimi, Ali Mafi, Mostafa Nejat, Farhad Sahebkar, Amirhossein J Ophthalmic Vis Res Original Article PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. RESULTS: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. CONCLUSION: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4329699/ /pubmed/25709764 http://dx.doi.org/10.4103/2008-322X.150803 Text en Copyright: © Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jadidi, Khosrow
Panahi, Yunes
Ebrahimi, Ali
Mafi, Mostafa
Nejat, Farhad
Sahebkar, Amirhossein
Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title_full Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title_fullStr Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title_full_unstemmed Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title_short Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
title_sort topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329699/
https://www.ncbi.nlm.nih.gov/pubmed/25709764
http://dx.doi.org/10.4103/2008-322X.150803
work_keys_str_mv AT jadidikhosrow topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury
AT panahiyunes topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury
AT ebrahimiali topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury
AT mafimostafa topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury
AT nejatfarhad topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury
AT sahebkaramirhossein topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury